Aclaris therapeutics functions as a pharmaceutical company, with the intent of identifying, developing, and the commercialization of medicines and therapies so that it can be best served in the dermatology, medical, and immunology sector. This biopharmaceutical company is registered under NASDAQ as NASDAQ: ACRS at https://www.webull.com/quote/nasdaq-acrs. The company has its roots in the United States of America. It strives to bring innovative therapies in the field of dermatology with both medical and aesthetic sense. This company was founded by dermatologists and had an efficient and extensive team working on the commercialization and development of dermatologic treatments.
Stock related news of NASDAQ: ACRS
The physician-led bio-pharmaceutical company has its stock standing currently at 2.28, with an estimated high of 5.00 and a low estimate of 3.500. According to the analysts of Wall Street and the insiders, it is a good and strong buy. The financial health and growth prospects show that NASDAQ: ACRS have the potential to outperform the market, and the recent changes in the price and its earnings indicate that the stocks can be overvalued in the future. The investors can feel safe with their investment, and with the predictions of a good buy, anyone wanting to invest too can place their bets on it.
Will the NASDAQ: ACRS stock price rise?
According to the insiders and the Wall Street analysts, the current consensus is to buy the stock in Aclaris therapeutics. This has been steady since June and has remained unchanged from a buy rating. So it can turn out to be a safe buy for new investors.
About Aclaris therapeutics
If you are about to invest in this biopharmaceutical company, here are a few things you need to know:
- Aclaris Therapeutics, Inc was incorporated on July 13th, 2012
- It is a physician-led bio-pharmaceutical company.
- The company has its focus on identifying, development, and the commercialization of drugs and therapies to serve in the field of dermatology, medical, and immunology sectors.
- It has its headquarters in Wayne, Pennsylvania in the United States of America.
- The company has about 50 to 200 employees.
- It is a public entity.
- Its current stock price stands at 2.28 with a high of 5.00 and a low of 3.5
- The analysts predict that it is a good buy.
The above is the insight on NASDAQ: ACRS if you are interested in investing in the stock.
The bottom line
The company that is based on pharmaceuticals and is keen on discovering medications for immunoinflammatory diseases and are in the clinical trial phases will hit the market with its completion. With everything looking good for the company, the stocks are sure to rise as predicted. You can get free stock from some stock apps. Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.